Is prior authorization of topical tretinoin for acne cost effective?

American Journal of Managed Care

Volumn 5, Issue 4, 1999, Pages 457-463

  Feldman, Steven R ^a   Fleischer Jr , Alan B ^a   Chen, G John ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

ACNE; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; HEALTH INSURANCE; HUMAN; INFANT; PRIORITY JOURNAL; REIMBURSEMENT; TOPICAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG UTILIZATION; HEALTH CARE SURVEYS; HUMANS; INFANT; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MIDDLE AGED; RETROSPECTIVE STUDIES; TRETINOIN;

EID: 0032963668     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: Research in need of discipline. Milbank Q 1993;71:217-252.
2. Kreling DH, Mucha RE. Drug product management in health maintenance organizations. Am J Hosp Pharm 1992;49:374-381.
3. Gondek K. Prescription drug payment policy: Past, present, and future. Health Care Financ Rev 1994;15:1-7.
4. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-239.
5. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of non-steroidal antiinflammatory drugs by Medicaid patients. New Engl J Med 1995;332:1612-1617.
6. Lennard EL, Feinberg PE. Overview of the New York State program for prescription drug benefits. Am J Hosp Pharm 1994;51:2944-2948.
7. Schlesinger MJ, Gray BH, Perreira KM. Medical professionalism under managed care: The pros and cons of utilization review. Health Aff 1997;16(1):106-124.
8. Prager LO. Standards suggested to reduce managed care hassles. American Medical News 1998;29(41):9.
9. Melski JW, Arndt KA. Current concepts: Topical therapy for acne. New Engl J Med 1980;302:503-506.
10. Haas AA, Arndt KA. Selected therapeutic applications of topical tretinoin. J Am Acad Dermatol 1986;15:870-877.
11. Gilchrest BA. Treatment of photodamage with topical tretinoin: An overview. J Am Acad Dermatol 1997;36:S27-S36.
12. McConnell RC, Fleischer AB Jr, Williford PM, Feldman SR. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: An analysis of the National Ambulatory Medical Care Survey, 1990-1994. J Am Acad Dermatol 1998;38:221-226.
13. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996;135:60-64.
14. Owen JA Jr. Prior authorization made simple. Va Med Q 1993;120:184-185.